Results 241 to 250 of about 1,321,964 (375)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

open access: yesHepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres   +21 more
wiley   +1 more source

Rethinking Chlorine: Essential Chemical or Replaceable Risk?

open access: yesChemSusChem, EarlyView.
Chlorine is essential for the production of plastics and pharmaceuticals but poses significant safety and environmental risks. Herein, processes are presented that substitute chlorine or reduce its demand. Where indispensable, trichloride‐ and bichloride‐based ionic liquids could enhance safety and streamline the integration of renewable energy ...
Johannes Schwan   +6 more
wiley   +1 more source

Identification of novel neutralizing determinants for protection against HCV

open access: yesHepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua   +12 more
wiley   +1 more source

OMIP‐114: A 36‐Color Spectral Flow Cytometry Panel for Detailed Analysis of T Cell Activation and Regulation in Small Human Blood Volumes

open access: yesCytometry Part A, EarlyView.
ABSTRACT This 36‐color flow cytometry panel is designed to characterize multiple lymphocyte compartments, with a focus on T cells, their memory subpopulations, and immune checkpoints in human whole blood samples. In clinical settings, the amount of blood available from patients for scientific research is often limited.
Marie‐Theres Thieme‐Ehlert   +3 more
wiley   +1 more source

Nicotinamide riboside and pterostilbene reduces markers of hepatic inflammation in NAFLD: A double‐blind, placebo‐controlled clinical trial

open access: yesHepatology, EarlyView., 2022
NRPT 1X reduces ALT and ceramide 14:0 in 65% of subjects as compared to only 28% in the placebo group. Abstract Background and Aims The prevalence of NAFLD is increasing globally and on a path to becoming the most frequent cause of chronic liver disease. Strategies for the prevention and treatment of NAFLD are urgently needed.
Ryan W. Dellinger   +7 more
wiley   +1 more source

Unhealthy Behaviours and All-Cause Mortality Among People With Chronic Hepatitis B, With and Without Hepatitis Delta (ANRS CO22 HEPATHER). [PDF]

open access: yesJ Viral Hepat
Ramier C   +9 more
europepmc   +1 more source

Epidemiology of common allergic diseases in China: Current position and implications

open access: yesEye &ENT Research, EarlyView.
Abstract The prevalence of common allergic diseases, including allergic rhinitis, asthma, atopic dermatitis, and food allergy, has increased dramatically with rising industrialization in China, leading to a significant socio‐economic burden.
Xu Xu   +4 more
wiley   +1 more source

Lichen Planus Pigmentosus as a Cutaneous Extrahepatic Manifestation of Chronic Hepatitis C Virus Infection: A Case Report. [PDF]

open access: yesInt Med Case Rep J
Avriyanti E   +7 more
europepmc   +1 more source

Transendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.
Abstract Aims The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.
Jerome Roncalli   +17 more
wiley   +1 more source

Home - About - Disclaimer - Privacy